Oncology nurses are the primary and best resource for patients to manage chemotherapy-induced nausea and vomiting (CINV)—identify the patients who might be suitable for SANCUSO
Patients may experience difficulty swallowing as a result of certain cancer types (eg, head and neck), or treatment regimens9
Combination radiation/chemotherapy contributes to oral mucositis and difficulty swallowing10
Malignancy-associated delayed gastric emptying may lead to changes in the absorption of orally administered drugs such as antiemetics11
The risk of oral mucositis increases with certain chemotherapeutic agents or combination radiation/chemotherapy10,b,c
You may have patients with chemotherapy-induced nausea and vomiting (CINV) who are appropriate for SANCUSO. Request a sample at no cost to see if SANCUSO is the right option for your patients.Request Sample
You may have patients with CINV who are ready for SANCUSO. Now you can receive updates about SANCUSO and learn about new resources as they become available.Stay Informed
Sancuso® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.
Sancuso is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system.
The most common adverse reaction (≥ 3%) is constipation.
You are encouraged to report suspected adverse reactions to Cumberland Pharmaceuticals Inc. at 1-800-Sancuso or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.